Insider Selling: KALA BIO, Inc. (NASDAQ:KALA) CFO Sells 1,706 Shares of Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 1,706 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $13,016.78. Following the sale, the chief financial officer now owns 68,581 shares in the company, valued at approximately $523,273.03. This trade represents a 2.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KALA BIO Price Performance

KALA BIO stock opened at $6.82 on Thursday. The firm has a market capitalization of $31.44 million, a PE ratio of -0.55 and a beta of -2.11. KALA BIO, Inc. has a 12-month low of $4.21 and a 12-month high of $9.25. The firm has a 50-day moving average price of $6.71 and a 200-day moving average price of $6.32. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. As a group, equities research analysts forecast that KALA BIO, Inc. will post -10.84 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of KALA BIO in a research report on Friday, November 15th.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.